Survodutide
Also known as: BI 456906, GLP-1/glucagon dual agonist
Survodutide is a catalog-expanded glp1 entry in ProtoComp's source-backed compound corpus. It is included for search, calculator math, stack awareness, and future research curation based on expand compound catalog, explicit_target_list, local_seed, project_target. Published dosing, cycle length, and clinical-use claims are intentionally left null until compound-specific evidence is reviewed.
Phase 2 obesity trial used dose-escalation up to 6 mg/week over 46 weeks. Phase 3 program ongoing for obesity and MASH.
No cycle range recorded.
Contraindications
- • Personal or family history of medullary thyroid carcinoma (class label)
Common side effects
- • Nausea
- • Vomiting
- • Diarrhea
- • Decreased appetite
- • Headache
Serious risks
- • Pancreatitis risk (class effect)
- • Glucagon-mediated transient hyperglycemia in non-diabetic users (mechanism-related)
Drug interactions
- • Insulin
- • Sulfonylureas
Requires monitoring
- • Blood glucose
- • Heart rate
Pregnancy / breastfeeding
Avoid — limited human data
- Glucagon agonism increases energy expenditure but can transiently raise blood glucose — distinct mechanism vs pure GLP-1 agonists
- Not yet approved — investigational only
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.